^
    Back
    Association details:
    Biomarker:CDKN2A-DT deletion
    Cancer:Glioma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    AACR-II 2020
    Title:

    Molecular subtype specific biomarkers improve prediction of temozolomide therapy in low grade glioma

    Excerpt:
    C9orf53, homozygous deletion in 40% IDHwt patients, significantly correlated with PFS (p=0.03) and OS (p < 0.01) in IDHwt cohort.